

# Application for Quotation of Additional Securities

File Reference:

I:\Issuers\Firms\website forms\documents 2016\issuers\NSX Quotation of Additional Securities.doc



# Table of Contents

|   |   |
|---|---|
| INTRODUCTION .....  | 2 |
| NEW ISSUE ANNOUNCEMENT, APPLICATION FOR QUOTATION OF ADDITIONAL<br>SECURITIES AND AGREEMENT ..... | 3 |
| PART 1 - ALL ISSUES .....   | 3 |
| PART 2 - BONUS ISSUE OR PRO RATA ISSUE.....   | 5 |
| PART 3 - QUOTATION OF SECURITIES .....  | 7 |
| ADDITIONAL SECURITIES FORMING A NEW CLASS OF SECURITIES.....                                      | 7 |
| QUOTATION AGREEMENT .....   | 9 |

## Introduction

To ensure the efficient processing of this form by NSX, please:

1. Adhere to the suggested number of the annexures required by this form.
2. Complete **all** statements and questions in this form. (NSX can provide an electronic version of this form on request).





# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to NSX as soon as available. Information and documents given to NSX become NSX's property and may be made public.

Introduced 11 March 2004. Revised 7 March 2016.

Name of entity

PYX Resources Limited

ABN/ACN

30 073 099 171

We (the entity) give NSX the following information.

## Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- |   |  |
|---|--|
| 1 Class of securities issued or to be issued  | Fully Paid Ordinary Shares (Shares)  |
| 2 Number of securities issued or to be issued (if known) or maximum number which may be issued  | 2,436,438 Shares   |
| 3 Principal terms of the securities (eg, if options, exercise price and expiry date; if partly paid securities, the amount outstanding and due dates for payment; if convertible securities, the conversion price and dates for conversion)   | The Shares are fully paid ordinary shares in the company and rank equally with existing ordinary shares. |
| 4 Do the securities rank equally in all respects from the date of allotment with an existing class of quoted securities?<br><br>If the additional securities do not rank equally, please state:<br><ul style="list-style-type: none"> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul> | The Shares rank equally in all respects from the date of allotment.                                      |



| 5           | Issue price or consideration  | £0.309 per Share   |        |       |             |   |           |  |            |  |           |  |           |   |  |
|-------------|---|--|--------|-------|-------------|---|-----------|--|------------|--|-----------|--|-----------|---|--|
| 6           | Purpose of the issue<br>(If issued as consideration for the acquisition of assets, clearly identify those assets) | Shares issued to Investor in accordance with the Company's announcements of 11 March 2022 and 2 December 2022.   |        |       |             |   |           |  |            |  |           |  |           |   |  |
| 7           | Dates of entering securities into uncertificated holdings or despatch of certificates                             | 5 January 2023   |        |       |             |   |           |  |            |  |           |  |           |   |  |
| 8           | Number and class of all securities quoted on NSX (including the securities in clause 2 if applicable)             | <table border="1"> <thead> <tr> <th data-bbox="774 840 1085 873">Number</th> <th data-bbox="1085 840 1386 873">Class</th> </tr> </thead> <tbody> <tr> <td data-bbox="774 873 1085 1086">443,785,538</td> <td data-bbox="1085 873 1386 1086">ORD</td> </tr> </tbody> </table>   | Number | Class | 443,785,538 | ORD   |           |  |            |  |           |  |           |   |  |
| Number      | Class   |  |        |       |             |   |           |  |            |  |           |  |           |   |  |
| 443,785,538 | ORD   |  |        |       |             |   |           |  |            |  |           |  |           |   |  |
| 9           | Number and class of all securities not quoted on NSX (including the securities in clause 2 if applicable)         | <table border="1"> <thead> <tr> <th data-bbox="774 1120 1085 1153">Number</th> <th data-bbox="1085 1120 1386 1153">Class</th> </tr> </thead> <tbody> <tr> <td data-bbox="774 1153 1085 1232">537,500</td> <td data-bbox="1085 1153 1386 1232">Unlisted options (\$1.00, expiry 22-Feb-2023)</td> </tr> <tr> <td data-bbox="774 1232 1085 1310">2,083,431</td> <td data-bbox="1085 1232 1386 1310">Unlisted options (£0.86, expiry 21-Mar-2025)</td> </tr> <tr> <td data-bbox="774 1310 1085 1534">16,980,000</td> <td data-bbox="1085 1310 1386 1534">Performance Rights convertible into a maximum of 20,220,000 Shares, subject to the achievement of milestones</td> </tr> <tr> <td data-bbox="774 1534 1085 1612">3,000,000</td> <td data-bbox="1085 1534 1386 1612">Unlisted warrants (£1.00, expiry 7-Oct-2025)</td> </tr> <tr> <td data-bbox="774 1612 1085 1702">2,323,645</td> <td data-bbox="1085 1612 1386 1702">Unlisted options (£0.45, expiry 6-Dec-2025)</td> </tr> </tbody> </table> | Number | Class | 537,500     | Unlisted options (\$1.00, expiry 22-Feb-2023) | 2,083,431 | Unlisted options (£0.86, expiry 21-Mar-2025) | 16,980,000 | Performance Rights convertible into a maximum of 20,220,000 Shares, subject to the achievement of milestones | 3,000,000 | Unlisted warrants (£1.00, expiry 7-Oct-2025) | 2,323,645 | Unlisted options (£0.45, expiry 6-Dec-2025) |  |
| Number      | Class   |  |        |       |             |   |           |  |            |  |           |  |           |   |  |
| 537,500     | Unlisted options (\$1.00, expiry 22-Feb-2023)   |  |        |       |             |   |           |  |            |  |           |  |           |   |  |
| 2,083,431   | Unlisted options (£0.86, expiry 21-Mar-2025)  |  |        |       |             |   |           |  |            |  |           |  |           |   |  |
| 16,980,000  | Performance Rights convertible into a maximum of 20,220,000 Shares, subject to the achievement of milestones      |  |        |       |             |   |           |  |            |  |           |  |           |   |  |
| 3,000,000   | Unlisted warrants (£1.00, expiry 7-Oct-2025)  |  |        |       |             |   |           |  |            |  |           |  |           |   |  |
| 2,323,645   | Unlisted options (£0.45, expiry 6-Dec-2025)   |  |        |       |             |   |           |  |            |  |           |  |           |   |  |
| 10          | Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)                | Not applicable   |        |       |             |   |           |  |            |  |           |  |           |   |  |



## Part 2 - Bonus issue or pro rata issue

- |           |   |                      |
|-----------|---|----------------------|
| <b>11</b> | Is security holder approval required?   | <input type="text"/> |
| <b>12</b> | Is the issue renounceable or non-renounceable?  | <input type="text"/> |
| <b>13</b> | Ratio in which the securities will be offered   | <input type="text"/> |
| <b>14</b> | Class of securities to which the offer relates  | <input type="text"/> |
| <b>15</b> | Record date to determine entitlements   | <input type="text"/> |
| <b>16</b> | Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?  | <input type="text"/> |
| <b>17</b> | Policy for deciding entitlements in relation to fractions   | <input type="text"/> |
| <b>18</b> | Names of countries in which the entity has security holders who will not be sent new issue documents<br><br><small>Note: Security holders must be told how their entitlements are to be dealt with.</small> | <input type="text"/> |
| <b>19</b> | Closing date for receipt of acceptances or renunciations  | <input type="text"/> |
| <b>20</b> | Names of any underwriters   | <input type="text"/> |
| <b>21</b> | Amount of any underwriting fee or commission  | <input type="text"/> |
| <b>22</b> | Names of any brokers to the issue   | <input type="text"/> |
| <b>23</b> | Fee or commission payable to the broker to the issue  | <input type="text"/> |
| <b>24</b> | Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders  | <input type="text"/> |





- 25** If the issue is contingent on security holders' approval, the date of the meeting
- 26** Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled
- 27** If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
- 28** Date rights trading will begin (if applicable)
- 29** Date rights trading will end (if applicable)
- 30** How do security holders sell their entitlements *in full* through a broker?
- 31** How do security holders sell *part* of their entitlements through a broker and accept for the balance?
- 32** How do security holders dispose of their entitlements (except by sale through a broker)?
- 33** Despatch date





### Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of securities  
(tick one)

(a)  X Securities described in Part 1

(b)  All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35  If the securities are equity securities, the names of the 20 largest holders of the additional securities, and the number and percentage of additional securities held by those holders

36  If the securities are equity securities, a distribution schedule of the additional securities setting out the number of holders in the categories  
1 - 1,000  
1,001 - 5,000  
5,001 - 10,000  
10,001 - 100,000  
100,001 and over

37  A copy of any trust deed for the additional securities

Entities that have ticked box 34(b)

38 Number of securities for which quotation is sought

39 Class of securities for which quotation is sought





**40** Do the securities rank equally in all respects from the date of allotment with an existing class of quoted securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

|  |
|--|
|  |
|--|

**41** Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another security, clearly identify that other security)

|  |
|--|
|  |
|--|

**42** Number and class of all securities quoted on NSX (*including* the securities in clause 38)

| Number | Class |
|--------|-------|
|        |       |







# Quotation agreement

1 Quotation of our additional securities is in NSX's absolute discretion. NSX may quote the securities on any conditions it decides.

2 We warrant the following to NSX.

- The issue of the securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those securities should not be granted quotation.
- An offer of the securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

**Note:** An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any securities to be quoted and that no-one has any right to return any securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the securities be quoted.
- We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the securities to be quoted, it has been provided at the time that we request that the securities be quoted.
- If we are a trust, we warrant that no person has the right to return the securities to be quoted under section 1019B of the Corporations Act at the time that we request that the securities be quoted.

3 We will indemnify NSX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give NSX the information and documents required by this form. If any information or document not available now, will give it to NSX before quotation of the securities begins. We acknowledge that NSX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: ..... Date: 5 January 2023  
(Company secretary)

Print name: Louisa Martino





5 January 2023

Company Announcements Office  
National Stock Exchange of Australia Limited  
1 Blich Street  
Sydney NSW 2000

Dear Sir/Madam

**Notice given under section 708A(5) of the Corporations Act**

This notice is given by PYX Resources Limited (**Pyx**, or the **Company**) under section 708A(5) of the *Corporations Act 2001* (Cth) (**Act**).

On Thursday, 5 January 2023 the Company issued 2,436,438 shares without disclosure under Part 6D.2 of the Act.

As at the date of this notice, the Company has complied with:

- (a) the provisions of Chapter 2M of the Act as they apply to the Company; and
- (b) section 674 of the Act.

The Company confirms that, as at the date of this notice, there is no information that:

- (a) has been excluded from a continuous disclosure notice given to NSX in accordance with the NSX Listing Rules; and
- (b) investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:
  - (1) the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
  - (2) the rights and liabilities attaching to fully paid ordinary shares.

Yours faithfully  
**PYX Resources Limited**

A handwritten signature in black ink, appearing to read 'Louisa Martino', written over a light blue horizontal line.

Louisa Martino  
Company Secretary